Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cytokinetics (NQ: CYTK ) 51.32 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cytokinetics < Previous 1 2 3 4 5 6 7 Next > 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. Via InvestorPlace Masters In Trading - Saturday, March 16 March 16, 2024 In this snippet from Friday's trading session, I review my various trades from the past week. Via Talk Markets Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today March 15, 2024 Via Benzinga 7 Biotech Stocks to Buy as Sector Rotation Ramps Up March 13, 2024 With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. Via InvestorPlace Super Micro, Deckers To Join S&P 500 Index March 01, 2024 They'll replace Whirlpool and Zions Bancorp on March 18. Via Investor's Business Daily Topics Stocks Exposures US Equities Unpacking the Latest Options Trading Trends in Cytokinetics February 28, 2024 Via Benzinga Here's How Much $1000 Invested In Cytokinetics 10 Years Ago Would Be Worth Today February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga Overbought, Overextended - What's The Buzz In S&P 500 Now? February 14, 2024 Here are the red flags you need to be aware of in this current market and the directional bias for the long-term, swing and immediate term. Via Talk Markets Topics Stocks Exposures US Equities Here's How Much $1000 Invested In Cytokinetics 5 Years Ago Would Be Worth Today February 09, 2024 Via Benzinga 3 Biotech Stocks to Buy for the Next Bull Run: February 2024 February 08, 2024 These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. Via InvestorPlace How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month February 08, 2024 Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease. Via Investor's Business Daily Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session February 05, 2024 U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday. Shares of Banco Santander, S.A. (NYSE: SAN) shares fell sharply during today’s pre-market trading. Via Benzinga Topics Stocks Exposures US Equities Here's How Much $100 Invested In Cytokinetics 5 Years Ago Would Be Worth Today February 02, 2024 Via Benzinga 3 Healthcare Stocks at 52-Week Lows: Buy or Bye? January 26, 2024 Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. Via InvestorPlace Biotech Playbook: Small Caps Show Momentum Peaking During January 15, 2024 The momentum of selected stocks was strong up until early January was encouraging but we need less volatility in period ahead to conform a new bull market. Via Talk Markets 10 Health Care Stocks With Whale Alerts In Today's Session January 15, 2024 Via Benzinga Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst January 12, 2024 Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed... Via Benzinga Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition January 11, 2024 Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 11, 2024 Via Benzinga Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday January 11, 2024 U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. (NYSE: ASPN) fell sharply during Thursday’s session after the company issued a... Via Benzinga Topics Stocks Exposures US Equities Bullish Continuation In '24? 3 Market Areas To Watch January 10, 2024 This article discusses 3 market areas that should outperform dramatically over the next 12 months... Via Talk Markets What's Been Happening With Cytokinetics Stock? January 09, 2024 Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session January 09, 2024 Via Benzinga Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today? January 08, 2024 Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). Via Benzinga Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal January 08, 2024 The company is working on a treatment for a disease that can lead to heart failure. Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's Pre-Market Session January 08, 2024 Via Benzinga CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday January 05, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session January 04, 2024 Via Benzinga 7 Stocks Primed for a Spectacular Comeback in 2024 January 03, 2024 Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.